Full Text View
Tabular View
No Study Results Posted
Related Studies
Study to Evaluate the Safety and Performance of the Xpert(TM) Stent in Treating Below-the-Knee Lesions in Patients Undergoing Percutaneous Intervention for Chronic Critical Limb Ischemia (XCELL)
This study is currently recruiting participants.
Verified by VIVA Physicians, August 2007
First Received: August 9, 2007   Last Updated: October 4, 2007   History of Changes
Sponsors and Collaborators: VIVA Physicians
Prairie Education and Research Cooperative
Information provided by: VIVA Physicians
ClinicalTrials.gov Identifier: NCT00515346
  Purpose

The purpose of this study is to evaluate the safety and performance of the Xpert(TM) self-expanding stent in infrapopliteal lesions as part of an overall treatment strategy in patients undergoing percutaneous intervention for the treatment of documented chronic critical limb ischemia (CLI).


Condition Intervention Phase
Chronic Critical Limb Ischemia
Peripheral Vascular Diseases
Device: Xpert(TM) Self-expanding Transhepatic Biliary Stent System
Phase I

Study Type: Interventional
Study Design: Treatment, Open Label, Single Group Assignment
Official Title: Phase 1 Study of Xpert(TM) Nitinol Stenting for Critically Ischemic Lower Limbs

Resource links provided by NLM:


Further study details as provided by VIVA Physicians:

Primary Outcome Measures:
  • Amputation free survival at 12 months in the target limb. Amputation for the primary endpoint is defined as a major, unplanned, amputation of the target limb through the 12 month visit where prosthesis is required for standing or walking. [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Assess improvement in wound healing; assess restenosis; measure target lesion revascularization to maintain patency at 12 months; measure ankle/brachial improvement level; assess stent integrity; characterize improvement in health related quality of life [ Time Frame: 2 years ]

Study Start Date: July 2006
Estimated Study Completion Date: December 2008
Detailed Description:

Peripheral arterial disease (PAD) of the lower extremities affects roughly 25 million Americans annually. The diabetic population is particularly prone to the most severe clinical problems associated with PAD and the amputation rate amongst such patients is elevated five-fold. It has been shown that patients who undergo amputation for PAD/CLI have a much higher mortality rate in the months that follow.

Despite medical advances in the fields of pharmacology and wound care, the vast majority of patients who present with CLI will ultimately require amputation in the absence of improved blood flow. Recently, much attention has been directed towards less invasive endovascular solutions for treating patients with CLI. This study will evaluate approximately 140 subjects with Rutherford Class IV-VI PAD in a multi-center study in order to accurately estimate limb salvage rates for this treatment.

  Eligibility

Ages Eligible for Study:   18 Years to 89 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Patient has documented wound care greater than or equal to 2 weeks prior to enrollment
  • Subject understands the duration of the study and its follow up visit requirements
  • Female subjects of childbearing potential have a negative pregnancy test less than 7 days before the procedure and are willing to use a reliable method of birth control for the duration of study participation
  • Subject has documented chronic critical limb ischemia in the target limb for two weeks with Rutherford Category 4, 5 or 6
  • Subject must have one of 5 approved non-invasive test results of the target limb within two weeks of enrollment.

Exclusion Criteria:

  • Life expectancy of less than 12 months
  • Cerebrovascular accident (CVA) or myocardial infarction (MI) within 3 months prior to enrollment
  • Inability to walk (with assistance is accepted)
  • Previous bypass surgery to target limb less than 30 days prior to study procedure
  • Acute thrombus at the lesion site(s)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00515346

Contacts
Contact: James D. Joye, DO 650-969-8600 jjoye@vivapvd.com

Locations
United States, California
VIVA Physicians Inc. Recruiting
San Jose, California, United States, 95123
Principal Investigator: James D. Joye, DO            
Sponsors and Collaborators
VIVA Physicians
Prairie Education and Research Cooperative
Investigators
Principal Investigator: James D. Joye, DO VIVA Physicians Inc.
  More Information

Additional Information:
No publications provided

Study ID Numbers: G060029
Study First Received: August 9, 2007
Last Updated: October 4, 2007
ClinicalTrials.gov Identifier: NCT00515346     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by VIVA Physicians:
CLI
Critical Limb Ischemia

Study placed in the following topic categories:
Peripheral Vascular Diseases
Vascular Diseases
Ischemia

Additional relevant MeSH terms:
Pathologic Processes
Peripheral Vascular Diseases
Vascular Diseases
Cardiovascular Diseases
Ischemia

ClinicalTrials.gov processed this record on September 04, 2009